爬壁机器人检测系统

Search documents
超研股份(301602) - 301602超研股份投资者关系管理信息20250919
2025-09-19 09:50
Group 1: Company Strategy and Focus Areas - The company aims to enhance its core competitiveness through industrial investments, focusing on the medical imaging and non-destructive testing sectors [2][3] - The company is actively seeking acquisition opportunities that align with its strategic development [2][3] - The company plans to expand its product portfolio through both depth and breadth, targeting cross-sector development [2][3] Group 2: Product Development and Market Position - The company has developed a portable multi-modal medical imaging system for emergency rescue applications, integrating portable DR and ultrasound devices [3][4] - The company’s industrial ultrasonic testing equipment is widely used in aerospace, petrochemicals, energy, and transportation sectors [4][5] - Key products include multi-modal medical imaging systems, specialized ultrasound diagnostic equipment, and automated non-destructive testing devices, which are expected to drive future revenue growth [5][6] Group 3: Research and Development - The company has participated in multiple national and provincial major research projects, with details disclosed in its prospectus and periodic reports [4][5] - The company has made advancements in AI-based breast cancer screening technology, enhancing the accuracy and efficiency of early detection [5][6] Group 4: Marketing and Sales Strategy - In 2025, the company will adjust its marketing strategy, focusing on major cities like Guangzhou, Shenzhen, Shanghai, and Beijing to strengthen its domestic and overseas marketing efforts [7][8] - The company aims to enhance its marketing network by attracting high-quality domestic and international distributors and improving local customer service capabilities [7][8] Group 5: Revenue Contribution - The sales revenue from surgical robots and automated non-destructive testing equipment constitutes a significant portion of the company's overall revenue [8]
超研股份(301602) - 301602超研股份投资者关系管理信息20250521
2025-05-21 10:12
证券代码:301602 证券简称:超研股份 汕头市超声仪器研究所股份有限公司 投资者关系活动记录表 编号:2025-002 答:您好,股票价格是多种因素综合影响的结果,公司一直以 提升经济效益为目标,重视公司市值成长,以期回报广大投资 者的信任。感谢您的关注! 4、请问公司预计未来业绩增长点会出在哪个方向? 答:您好,公司未来的盈利增长将主要来源于将超声、射线、 人工智能技术与用户需求相结合不断推出的创新型产品。如公 司在国内率先提出了医用超声扫描标准化和诊断智能化的解 决方案,并已经应用于智能乳腺全容积超声诊断系统等产品, 为超声产品在专科诊疗领域推广应用带来了广阔的增长空间; 将可免防护便携式 DR 与掌上超声相结合,为应急救援领域等 带来全新的多模态影像诊断工具。在无损检测领域,2024 年 推出了爬壁机器人检测系统,能够代替人工在特殊环境中进行 超声检测和视觉检测,降低作业风险也提高了检测效率和检测 质量。以上这些都是未来公司业绩新的增长点。感谢您的关注! 5、董事长好!公司刚上市半年,7 月份就解禁 350 多万股会 对目前的股价有重大影响吗? 答:您好,股票价格受宏观环境、行业政策、投资者偏好等多 ...